발생일자 2014.12.04 

사건번호 1:14-cv-01461 

법원국가 UNITED STATES OF AMERICA 

관할법원명 D.C.Delaware(지방법원) 

침해권리 특허 

원고명 Allergan, Inc./ Vistakon Pharmaceuticals, LLC ( 미국 / 외국기업 )  

피고명 Wilshire Pharmaceuticals, Inc. ( 미국 / 외국기업 )  

소송유형 침해금지 

[Allergan, Inc. et al v. Wilshire Pharmaceuticals, Inc.] 사건번호 1:14-cv-01461에 따르면 원고 Allergan, Inc./ Vistakon Pharmaceuticals, LLC는 피고 Wilshire Pharmaceuticals, Inc.을 상대로 특허 US8664215를 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다. 

분쟁결과 분쟁중 

산업분류 화학∙바이오 > 의약품 

계쟁제품 Alcaftadine ophthalmic solution 0.25%, generic version of Lastacaft

지재권번호/명칭

US8664215   Ocular allergy treatments with alcaftadine 

Ocular allergy treatments with alcaftadine

Abstract

Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.

 Claims

---

What is claimed is:

1. A method of treating a clinical symptom of ocular allergy, comprising administering once daily to the eye of a human patient with said clinical symptom of ocular allergy an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof.

2. The method of claim 1 wherein the ocular allergy is allergic conjunctivitis.

3. The method of claim 1 wherein the ophthalmic composition comprises from about 0.2% to about 0.35% by weight of alcaftadine.

4. A method of preventing ocular itching in a human patient exposed to a conjunctival allergen, comprising administering once daily to the eye of said human patient an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof, wherein prevention comprises inhibiting said ocular itching compared to a non-treated patient.

5. The method of claim 4 wherein the ophthalmic composition comprises from about 0.2% to about 0.35% by weight of alcaftadine.

6. The method of claim 4 wherein the ophthalmic composition comprises about 0.25% by weight of alcaftadine.

7. The method of claim 1 wherein the ophthalmic composition comprises about 0.25% by weight of alcaftadine.

8. The method according to claim 4 wherein said ophthalmic composition comprising alcaftadine is administered prior to exposure to a conjunctival allergen.

9. The method according to claim 4 wherein said ophthalmic composition comprising alcaftadine is administered after exposure to a conjunctival allergen.

10. The method according to claim 4 further comprising preventing conjunctival redness, chemosis, and lid edema in said human patient exposed to said conjunctival allergen wherein prevention comprises inhibiting said conjunctival redness, chemosis, and lid edema.

11. A method of preventing conjunctival redness, chemosis, and lid edema for a period exceeding 16 hours in a human patient exposed to a conjunctival allergen comprising administering once daily to the eye of said human patient an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof, wherein prevention comprises inhibiting said wherein prevention comprises inhibiting said conjunctival redness, chemosis, and lid edema compared to a non-treated patient.